Immunitybio Inc (IBRX) — Cash Flow-to-Debt Ratio
Latest as of September 2025:
-0.12x
Immunitybio Inc (IBRX) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of $-68.91 Million could theoretically repay 0% of its total liabilities ($569.82 Million) in one year. See financial agility of Immunitybio Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.12x
Operating CF / Total Liabilities
Operating Cash Flow
$-68.91 Million
USD
Total Liabilities
$569.82 Million
USD
Data as of
Sep 2025
Most recent filing
Immunitybio Inc Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Immunitybio Inc across 12 annual periods. For the full cash flow conversion analysis, see how efficiently does Immunitybio Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Immunitybio Inc (2013–2024)
Year-by-year debt coverage analysis for Immunitybio Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.45x | $-391.24 Million | $871.06 Million | ▼ -33.5% |
| 2023 | -0.34x | $-366.76 Million | $1.09 Billion | ▲ +19.1% |
| 2022 | -0.42x | $-337.51 Million | $812.18 Million | ▼ -7.9% |
| 2021 | -0.38x | $-274.42 Million | $712.82 Million | ▲ +23.8% |
| 2020 | -0.51x | $-171.72 Million | $339.87 Million | ▲ +92.5% |
| 2019 | -6.78x | $-152.11 Million | $22.44 Million | ▼ -284.3% |
| 2018 | -1.76x | $-63.38 Million | $35.94 Million | ▼ -14.2% |
| 2017 | -1.54x | $-48.78 Million | $31.60 Million | ▲ +3.7% |
| 2016 | -1.60x | $-38.59 Million | $24.08 Million | ▲ +31.3% |
| 2015 | -2.33x | $-25.30 Million | $10.85 Million | ▼ -4.7% |
| 2014 | -2.23x | $-5.35 Million | $2.40 Million | ▼ -1565.6% |
| 2013 | -0.13x | $-668.00K | $5.00 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.